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Abstract 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease involving the 
formation of cytoplasmic aggregates by proteins including TDP-43 and SOD1, in 
affected cells in the central nervous system (CNS). Pathology spreads from an 
initial site of onset to contiguous anatomical regions. There is evidence that for 
disease-associated proteins, including TDP-43 and SOD1, non-native protein 
conformers can promote misfolding of the natively folded counterparts, and cell-
to-cell transfer of pathological aggregates may underlie the spread of the disease 
throughout the CNS. A variety of studies have demonstrated that SOD1 is 
released by neuron-like cells into the surrounding culture medium, either in 
their free state or encapsulated in extracellular vesicles such as exosomes. 
Extracellular SOD1 can then be internalised by naïve cells incubated in this 
conditioned medium, leading to the misfolding and aggregation of endogenous 
intracellular SOD1, an effect that propagates over serial passages. A similar 
phenomenon has also been observed with other proteins associated with protein 
misfolding and progressive neurological disorders, including tau, α-synuclein 
and both mammalian and yeast prions. Conditioned media experiments using 
TDP-43 have been less conclusive, with evidence for this protein undergoing 
intercellular transfer being less straightforward. In this review, we describe the 
properties of TDP-43 and SOD1 and look at the evidence for their respective 
abilities to participate in cell-to-cell transfer via conditioned medium, and 
discuss how variations in the nature of cell-to-cell transfer suggests that a 
number of different mechanisms are involved in the spreading of pathology in 
ALS.  
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Abbreviations 
 
ALS amyotrophic lateral sclerosis 
CFTR 
CNS 
cystic fibrosis transmembrane conductance regulator 
central nervous system 
CSF cerebrospinal fluid 
fALS familial ALS 
FTLD frontotemporal lobar degeneration 
LMN lower motor neurons 
sALS sporadic ALS 
UMN upper motor neurons 
WT wild-type 
MND motor neurone disease  
SOD1 copper-zinc superoxide dismutase 1 
FUS fused in sarcoma/translocated in liposarcoma 
TDP-43 
ThT 
Tar DNA-binding protein 43 
Thioflavin T 
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1 Amyotrophic lateral sclerosis and protein misfolding 
Amyotrophic lateral sclerosis (ALS), the most common form of motor neurone 
disease (MND), is a rapidly progressive neurodegenerative condition caused by 
the loss of upper (UMN) and lower motor neurons (LMN) in the central nervous 
system (CNS). This neuronal loss results in a range of symptoms that may 
include muscle weakness and wasting, limb rigidity and difficulty in swallowing, 
speaking and breathing, culminating in paralysis and eventually death.  
Symptoms usually present at a focal site of onset, often an upper or lower limb, 
before spreading to contiguous neuroanatomical regions [1,2]. The extension of 
clinical symptoms is accompanied by the spatiotemporal progression of 
pathology throughout the CNS [3-6], which is characterised by the deposition of 
aggregated proteins in affected cells. Familial ALS (fALS) accounts for 
approximately 10% of all cases of the disease, with the other 90% being sporadic 
(sALS); however, there is no evident difference in clinical presentation between 
sALS and fALS patients, suggesting that a common molecular mechanism 
underlies the disease. Misfolded Tar DNA-binding protein 43 (TDP-43) is the 
major component of the inclusions found by autopsy in the majority of both sALS 
and fALS patients, although in a small fraction of cases the inclusions primarily 
contain the proteins copper-zinc superoxide dismutase 1 (SOD1) or fused in 
sarcoma/translocated in liposarcoma (FUS) [7].   
 
1.1 TDP-43 
TDP-43 is a protein containing 414 amino acid residues and is encoded by the 
TARDBP gene. It belongs to a family of RNA binding proteins known as 
heterogeneous nuclear ribonucleoproteins (hnHRPs), but, unlike most members 
of this family, TDP-43 forms a homodimer even in the absence of RNA [8,9]. It 
has a range of physiological roles involving the control of transcription and 
translation, including splicing and the regulation of non-coding RNA [10].  TDP-
43 regulates its own mRNA levels through binding to the 3’UTR of the TDP-43 
transcript, such that high levels of protein downregulate endogenous TDP-43 
expression via a negative feedback loop. Only one ALS-associated mutation, 
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occurring in a region potentially important for RNA binding, has been found to 
interfere with this feedback loop [11]. It is possible, however, that TDP-43 
aggregates could also disrupt this process by sequestering functional protein, 
thus removing regulatory control over TDP-43 production [11].  
 
The accumulation of aggregated and post-translationally modified TDP-43 is 
considered a biochemical signature of ALS, and may play a significant role in 
driving pathogenesis. It was first identified as a component of inclusions in both 
sALS and frontotemporal lobar dementia (FTLD) by two different groups in 
2006, having previously been known to bind a motif in the HIV transactive 
response DNA, and to participate in a complex involved in the splicing of the 
cystic fibrosis transmembrane conductance regulator (CFTR) gene [12-14]. Since 
then, much work has been done to investigate the way in which TDP-43 
contributes to the onset and progression of ALS. Over 50 disease-associated 
mutations have been identified [10,15], the majority being located within an 
aggregation-prone region of the protein and appearing to enhance its 
aggregation propensity [16]. Under normal conditions TDP-43 is predominantly 
a nuclear protein, but in ALS and FTLD there is a loss of functional TDP-43 which 
results in detrimental effects on RNA metabolism, in combination with the 
cytosolic accumulation of aggregates that leads to neurotoxicity [17,18]. TDP-43 
aggregation culminates in the deposition of both round and skein-like 
cytoplasmic inclusions, often associated with depletion of the protein from the 
nucleus [13,14].  
 
TDP-43 contains two RNA recognition motifs (RRM1 and RRM2), which interact 
with nucleic acids, as well as a glycine-rich C-terminus. RRM1 is responsible for 
preferential binding of TDP-43 to UG-repeated motifs in RNA [19]. Almost all 
ALS-associated mutations in TDP-43 occur in the C-terminus within the glycine-
rich domain, strongly suggesting that the function of this domain is important in 
neurodegeneration [20]. The C-terminus not only mediates protein-protein 
interactions but also contains a region rich in glutamine (Q) and arginine (N) 
residues (Q/N rich region), which confers properties similar to those of yeast 
prions [21]. The similarity in sequence between the Q/N-rich region and yeast 
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prion domains may relate to its cellular function, as when the prion-like domain 
within the C-terminus of full-length TDP-43 tagged with GFP was replaced with 
the yeast prion domain of Sup35 in transfected cells, in vivo splicing assays 
showed that this construct regulated exon 9 skipping of the (CFTR) gene in the 
same way as WT TDP-43 does [16]. This observation suggests that the Q/N-rich 
region may have a functional role under normal conditions and only adopts an 
aggregation-prone conformation after a disease-triggering event [21]. The 
general consensus, based on a number of studies designed to pinpoint the key 
sequences for aggregation, suggest the critical sequence for aggregation is 
located between residues 286-353 [22], although there is evidence that the 
truncated C-terminal RRM2 domain (208-265) drives formation of non-amyloid 
fibrils, as confirmed by the amyloid detecting dye Thioflavin T (ThT), in vitro and 
in vivo [9].  While aggregates formed from C-terminal fragments or the full-length 
protein do not react with Congo Red, another dye used to confirm that 
aggregates are amyloid [23], two recent studies have found that the fluorescent 
dye Thioflavin-S, that also binds to amyloid species, binds to TDP-43 positive 
skein-like inclusions in a subset of ALS cases, suggesting that pathological TDP-
43 aggregates may in fact have amyloidogenic properties [24,25]. Studies using 
ALS patient brain lysate containing pathogenic TDP-43 have shown that this 
material can seed the formation of insoluble TDP-43 inclusions in cell cultures, 
and this can propagate between cells over serial passages [26,27].  
 
1.2 SOD1 
 The gene that encodes copper-zinc superoxide dismutase 1 (SOD1) was first 
associated with ALS in 1993, with mutations in this gene accounting for 20% of 
fALS cases [28,29]. Its canonical role is as a free radical scavenger, but there is 
emerging evidence that it may also act as a transcription factor [30] and an RNA 
binding protein [31].  It is highly stable in its native state, but may misfold in 
response to a variety of triggers, including oxidative stress.  Nearly 200 disease-
causative mutations have been identified throughout the sequence, all of which 
appear to converge on the exposure of hydrophobic surfaces that are normally 
buried within the molecule when natively folded [32]. Misfolding of SOD1 results 
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in a gain of function effect, with the presence of aggregates leading to cell death, 
and SOD1-ALS pathology is characterised by the deposition of conglomerate 
inclusions enriched in SOD1 that are normally negatively immunoreactive for 
TDP-43 [33].   
 
Eukaryotic WT SOD1 exists as a stable 32 kDa homodimer predominantly 
located in the cytoplasm, although it can also be found in the nucleus [34]. The 
homodimer adopts an eight-stranded Greek key β-barrel structure stabilised by 
an intra-subunit disulphide bond, and each subunit binds one copper atom and 
one zinc ion. These post-translational modifications all contribute to the stability 
of SOD1, making it exceptionally resistant to heat denaturation, and conferring 
the ability to retain function under denaturing conditions [35,36].  
 
It is thought that immature and unfolded SOD1, in a disulphide-reduced state 
that does not bind zinc or copper ions, is responsible for aggregation in vivo, 
although identifying the structure of the species involved is challenging due to 
the conformational heterogeneity of its non-native state. ALS-associated 
mutations, as well as aberrant post-translational modifications to the WT 
protein, destabilise SOD1 and cause it to misfold [37]. It is currently unclear 
whether or not amyloid fibrils are important in SOD1 mediated ALS, as SOD1 
positive inclusions from ALS patient tissue do not show Thioflavin-S or Congo 
Red binding [23]. SOD1 does, however, bind to ThT during in vitro aggregation 
assays [38]. Furthermore, computational modelling has identified amyloidogenic 
segments within the molecule that can be used to produce synthetic peptides 
that aggregate into structures with fibrillar morphology when imaged using 
transmission electron microscopy [39]. 
 
In vitro aggregation studies have been carried out with WT SOD1 and several 
mutational variants, under a range of different conditions to characterise the 
different types of aggregate species. Initial experiments used the apo WT SOD1 
variant where the cysteine residues at positions 6 and 11 were substituted by 
alanine and serine respectively (apo AS-WT SOD1) and showed this protein has 
similarities to WT SOD1 in terms of structure, stability and metal binding. It was 
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found to be possible to form fibrils from soluble apo AS-WT SOD1 at pH 3.5 in 
the presence of EDTA over a period of months and electron microscopy showed 
aggregates of mixed morphology including fibrils [40]. These conditions, 
however, are not close to physiological, and so further work has been done to 
explore aggregation under conditions more likely to be encountered inside a cell. 
Apo SOD1 containing an N-terminal His6 tag and where cysteine 6 and 11 were 
both mutated to serine (SS-SOD1) was observed to form insoluble amyloid fibrils 
at pH 7 and apo SOD1 where all four cysteines are reduced, thereby lacking the 
disulphide bond, was observed to form aggregates in physiological buffer 
conditions at 37°C with agitation overnight. These aggregates exhibit amyloid 
properties when analysed using a range of biophysical techniques and the fibrils 
were also found to seed the aggregation of soluble SOD1 [41]. Apo WT human 
SOD1 recombinantly expressed in yeast, thereby retaining all post-translational 
modifications occurring in vivo, has also been studied and observed to form 
fibrillar species under mild reducing conditions. It was also found that the 
presence of a small amount of disulphide reduced apo WT SOD1 was sufficient to 
induce fibril formation of apo WT SOD1, suggesting that destabilisation of the 
homodimer produces monomeric SOD1 nuclei that recruits apo WT SOD1 into 
the fibrils, providing a role for WT SOD1 in the disease process [42].  
 
Different SOD1 mutational variants have previously been observed to have a 
variety of aggregation propensities when expressed in cultured cells, enabling 
the behaviour of recombinant SOD1 variants in vitro to be compared to their 
intracellular aggregation [37]. Using motor-neuron like NSC-34 cells expressing 
different SOD1 variants tagged with eGFP, it was possible to quantify the number 
of aggregates present 48 h post-transfection. By plotting the end point ThT 
fluorescence versus the percentage of cells showing inclusions for each variant, it 
was evident that the aggregation propensity of SOD1 in vitro can predict its 
aggregation propensity in cells. Interestingly, the strongest correlation was 
between the in vitro aggregation propensity for specific variants and patient 
disease duration, which could be used to predict disease severity. It appears that 
the aggregation kinetics governing in vitro fibril formation and aggregation in 
mouse models are very similar, although this does not directly translate to 
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human disease [43]. Nevertheless, these strategies have provided a great deal of 
information regarding the folding and aggregation of SOD1 in disease. 
 SOD1 also participates in the cell-to-cell propagation of aggregates over serial 
passages [44,45], suggesting that protein aggregation represents an important 
and common pathogenic mechanism. Many mutations in genes encoding 
proteins other than TDP-43 and SOD1 have since been discovered, but 
histopathology mainly converges on the deposition of misfolded TDP-43, and in 
some cases, SOD1 or FUS, regardless of the initial cause of the disease [29].  
 
1.3 Other molecular players in ALS and FTLD: FUS, C9orf72 and tau 
FUS is another RNA binding protein that is normally found in the nucleus but 
shows enhanced aggregation propensity as a result of ALS-associated mutations, 
and is deposited in cytoplasmic inclusions in a small subset of both sALS and 
fALS cases (for review see [46]). One study has demonstrated that a mutational 
variant of FUS can seed the aggregation of WT FUS both in vitro and in vivo, 
however, there is currently no experimental evidence of cell-to-cell transfer of 
FUS aggregates in a similar manner to those of TDP-43 and SOD1 [47].   
 
A major discovery was made in 2011, when genomic sequencing revealed a 
noncoding GGGGCC nucleotide repeat expansion in the first intron of gene 
C9orf72 as the most common cause of familial ALS and FTLD, as well as 
accounting for a considerable proportion of sporadic cases [48,49]. While the 
presence of fewer than 30 repeats is now associated with disease, in affected 
patients this can reach up to hundreds or even thousands of repeats, although 
there is no clear relationship between the size of the nucleotide repeat expansion 
and either disease severity or age of onset [50]. Putative mechanisms of 
neurotoxicity include: loss of functional C9orf72 protein, production of toxic RNA 
foci and accumulation of different dipeptide repeats encoded by the 
hexanucleotide repeat expansions (for review see [50]), all of which are capable 
of disrupting normal cellular function.  Very recently it was shown that these 
dipeptide repeat proteins can undergo cell-to-cell transfer through direct 
intercellular contact as well as exosome dependent mechanisms [51].  
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No mutations in the MAPT gene encoding the microtubule-associated protein tau 
have so far been associated with ALS, but there appears to be an overlap in 
histopathology between hyperphosphorylated tau and TDP-43 in some cases of 
ALS with cognitive impairment, although the significance of this is unclear [52]. 
Tau pathology is more commonly found in diseases including Alzheimer’s 
disease and a subset of FTLD, collectively termed as tauopathies. Transfer of 
aggregated tau between cells has been demonstrated in several studies (for 
review see [53]), and there is evidence that different tau strains exist that are 
capable of serially propagating their distinct structural properties in both cell 
lines and in mice.   
 
1.4 Protein misfolding and aggregation in disease 
Protein misfolding and aggregation has been implicated in a number of 
increasingly prevalent human diseases ranging from neurodegeneration to 
diabetes [54]. The ability of a normally soluble peptide or protein to aggregate 
into ordered fibrils has been discovered to be a generic property of polypeptide 
chains, although aggregation propensity is, in part, encoded in the amino acid 
sequence [55]. Persistent protein misfolding in vivo arises either from natively 
folded proteins adopting an alternative conformation or through incorrect 
folding during synthesis [56]. This is a comparatively rare event as there are 
cellular strategies in place either to refold the protein into a functional structure 
or to degrade misfolded conformers. However, partially folded or misfolded 
proteins pose a problem because they are at greater risk of aberrant interactions 
with other molecules. This is because hydrophobic regions of the protein that are 
normally buried within the core of the molecule become exposed to the aqueous 
environment and can self-associate through hydrophobic interactions and 
hydrogen bonding, thereby losing solubility associated with the native state [54].  
Protein aggregates can adopt a variety of stable structures including amorphous 
assemblies, oligomeric species and amyloid fibrils. The latter species are of 
particular interest because they are highly structured self-associated protein 
multimers with characteristic physico-chemical properties.  
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Despite the number of proteins linked with misfolding diseases, there are no 
common features of their primary sequences or their secondary or tertiary 
structures [54]. Amyloid fibrils themselves share a remarkably similar structural 
nature, forming closely packed structures rich in β-sheet content. They form long 
thread-like filamentous structures that are approximately 10 nanometers in 
diameter, but can reach micrometers in length, with mature fibrils consisting of 
intertwining protofibrils. Their core architecture involves a cross-β structure 
that is highly stable due to the arrangement of backbone hydrogen bonding, 
which is a property shared by all polypeptide sequences. Amyloid fibrils may in 
fact be more thermodynamically stable than natively folded states, even under 
physiological conditions. As the conversion from soluble protein to fibrils 
requires intermolecular contacts, the thermodynamic stability of fibrils is 
increased at higher protein concentrations [55].  
 
Analysing the kinetics of amyloid formation has yielded a great deal of 
information on the process of converting soluble natively folded proteins to 
amyloid fibrils (figure 1). In the presence of a limited quantity of monomeric 
soluble protein, the reaction typically follows a sigmoidal curve over time, 
defined by a slow lag phase followed by a rapid growth phase, and then reaching 
a plateau once the pool of monomers is depleted. Soluble monomeric proteins 
initially polymerise through nucleation mechanisms generating oligomers, 
species that then form protofibrils, and finally mature fibrils. The rapid growth 
phase involves elongation of the aggregate by the addition of free monomers to 
the fibril ends, and also secondary processes, such as the fragmentation of fibrils 
to increase the number of growing ends, or via secondary nucleation in which a 
fibril acts as a catalytic site for free monomers to aggregate. These mechanisms 
contribute to the generation of more aggregates, demonstrating that amyloid 
growth is capable of rapid proliferation following the initial nucleation process 
[55].  
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Figure 1. Schematic representation of the kinetics of amyloid formation. Amyloid formation is 
characterised by an initial lag phase in which monomeric species nucleate and form oligomeric 
species followed by a growth phase of fibril formation, which occurs through elongation and 
secondary events (fragmentation and/or secondary nucleation). A plateau is reached when amyloid 
formation is in a steady state as free monomers (i.e. protein molecules) are no longer available. 
Like in other neurodegenerative disorders, including Alzheimer’s and 
Parkinson’s disease, the presence of aggregates is linked to ALS pathology; each 
condition is characterised by the progressive and gradual spread of an 
aggregated signature protein deposited in inclusions in a stereotypical pattern 
through the neuroaxis [57]. These observed generic characteristics have led to 
the emergent concept of ‘prion-like behaviour’ as a mechanism underlying the 
aggregation and spread of misfolded proteins in these diseases, which is a 
conceptual framework borrowed from prion diseases [56-58]. The mammalian 
cellular prion protein, PrPc, is a glycosyl-phosphatidylinositol anchored 
membrane-bound glycoprotein encoded by the PRNP gene that can misfold into 
the β-sheet rich pathological conformer PrPSc. What makes the prion unique is 
not its capacity to self-propagate through induced misfolding and amplification 
in an amyloidogenic manner, reflected by an incubation period of several years 
followed by a rapid clinical presentation phase, but by its transmissibility 
between individuals and, exceptionally, across species [59]. Such infectivity 
appears to occur without RNA or DNA driving replication, unlike conventional 
infectious agents such as bacteria or viruses, with the term ‘protein only 
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hypothesis’ sometimes used to refer to the causative agent of prion diseases [60]. 
To propagate pathology throughout the CNS, the pathological conformer is 
thought to leave an affected cell and to be taken up by surrounding cells, where it 
induces the conversion (also known as ‘seeding’) of endogenous natively folded 
protein counterparts into the pathological conformation, ultimately causing 
misfolding and aggregation to spread [61].  
 
Both mammalian and yeast prions share the ability to form amyloid fibrils, but 
while the former appears to be pathogenic, the latter are normally functional and 
can even be advantageous in yeast. Out of 20,000 human protein-encoding genes 
analysed, 240 genes have been identified as containing sequences related to 
yeast prion-like domains, which are typically enriched in polar, uncharged amino 
acids [62]. Thirty percent of these are RNA binding proteins, including TDP-43 
and FUS, indicating that these low complexity sequences are important for 
function under normal physiological conditions [62]. The prion-like domains, in 
particular of TDP-43, confers a high aggregation propensity [16], which may 
explain why many proteins containing these sequences may misfold and 
aggregate in neurodegenerative diseases.  SOD1 does not contain a prion-like 
domain, but shares many attributes with mammalian prions, including self-
replication in vitro and transfer of aggregates in culture [32].  
 
Prion-like propagation is rapidly gaining popularity as an explanation for the 
progressive intercellular spread of misfolded protein, but it does not entirely 
explain how proteins that are expressed throughout the nervous system during 
our life span, can start to misfold and aggregate in specific regions, before 
pathology disseminates to more distant areas[63]. The ‘selective vulnerability’ 
hypothesis puts forward the idea that certain neuronal populations within the 
CNS are more susceptible to insults than others, and as these stresses 
accumulate over time, they induce the misfolding and aggregation of endogenous 
protein in these cells. Stress signals are transmitted to other populations through 
diffusible extracellular factors or directly through trans-synaptic signaling, 
which causes aggregation in less susceptible populations [64]. It is very likely 
that these mechanisms operate in combination in neurodegenerative disease, 
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making it imperative that we work to fully characterise the process of cell-to-cell 
aggregate transfer and its relevance to neurodegenerative disease.    
 
Several subcellular mechanisms may contribute to cell-to-cell transmission of 
aggregates, but the process broadly depends on four events: 1) an aggregate 
passing across the membrane of the donor cell, 2) traversing the extracellular 
environment, 3) crossing the membrane of the recipient cell and 4) interacting 
with endogenous natively folded conformers and inducing misfolding [61,64]. 
The mammalian prion overcomes the first two stages as it is exposed to the 
extracellular environment from its location on the plasma membrane, and is 
secreted under normal physiological conditions. Most pathogenic misfolding 
proteins, however, are normally cytosolic, or in the case of TDP-43, shuttle 
between the nucleus and cytoplasm [64]. Several non-classical routes of entry 
have been suggested, some of which depend on direct contact between cells 
(tunneling nanotubes, transynaptic contacts), and some of which are contact 
independent (exosomes, naked aggregates) (figure 2) [65-67] (reviewed in [61]). 
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Figure 2. Diagram showing cell-to-cell transfer. The pathological propagative species must pass 
through the plasma membrane of the donor cell (1) to enter the extracellular environment (2), pass 
through the plasma membrane of the recipient cell (3) and then induce the conversion of non-
pathological protein into its pathological counterpart (4). In this diagram, the propagative species is 
represented by an oligomeric species; however, the exact structural nature of the transmissible 
species is not conclusively known. 
Cell-to-cell transfer of aggregates is less well-characterised in ALS compared to 
other neurodegenerative disorders such as Alzheimer’s or Parkinson’s diseases, 
but there remains a strong possibility that prion-like mechanisms are relevant to 
the pathogenesis of the disease (reviewed in [68]). Sporadic ALS patients have 
significantly elevated levels of either TDP-43 or SOD1 in their cerebrospinal fluid 
(CSF) compared to age matched controls, especially at earlier stages of the 
disease, which indicates that the proteins are released and circulate around the 
body during the disease process [69-71]. Exosomes, small endocytic vesicles that 
are secreted by most cell types into circulating fluids including the CSF, are 
already implicated with the spreading of a variety of pathological misfolded 
proteins [72]. Even cultured cells release exosomes and other secreted factors 
directly into the culture medium, allowing material to accumulate in the 
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extracellular environment over time [73]. Collecting medium from cells 
overexpressing a misfolding protein, here referred to as conditioned medium, 
and applying it to a fresh cell culture in order to observe internalisation, 
provides an important strategy for modelling contact-independent intercellular 
spread in vitro. Such experiments have been conducted in neuron-like cell 
cultures using both TDP-43 and SOD1. SOD1 appears to undergo cell-to-cell 
transfer via conditioned medium, and even propagates over serial passages in 
culture [66]. In contrast, however, those investigating this route for TDP-43 have 
not been able to demonstrate conclusively that it undergoes cell-to-cell transfer 
in the same way [27,74,75].   
 
In the next section of this review, we describe the evidence of cell-to-cell transfer 
via conditioned medium for a number of neurodegenerative diseases. We then 
describe the properties of SOD1 and TDP-43 and compare their respective 
abilities to participate in cell-to-cell transfer via conditioned medium based on 
the evidence so far, with a focus on experiments investigating neuron-to-neuron 
transfer in immortalised cell lines. We go on to discuss how these differences in 
routes of cell-to-cell transfer may implicate different mechanisms involved in the 
spreading of pathology in ALS.  
2 Conditioned medium as a route for cell-to-cell transfer 
The experimental paradigm of conditioned medium is dependent on a 
population of cells in culture that secrete factors into the extracellular 
environment (known as a donor population). A population of cells without prior 
exposure to the secreted material (the acceptor population) is then cultured in 
the conditioned medium to observe whether or not the material originating from 
the donor population can be internalised by the acceptor cells. Using conditioned 
medium provides a simpler system to explore cell-to-cell transfer than in vivo 
models, as well as providing much greater control over the experimental 
conditions.  
 
Conditioned medium experiments can be categorised according to one of four 
strategies (figure 3): 
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1) The donor and acceptor cultures are separated by a porous membrane or 
barrier to prevent cell-to-cell contact,  
2) The conditioned medium is collected from donor cells and applied to the 
acceptor culture, 
3) Components, such as exosomes, of the conditioned medium are isolated 
and applied to the acceptor culture, 
4) Complementary protein assay models, which employ a bioluminescent 
complementary fragment reporter system, such as luciferase, to label the 
protein of interest in order to report on its aggregation state in 
conditioned medium.  The protein of interest is labelled with one of two 
complementary fragments. Bioluminescence only occurs if the two 
complementary fragments are in close enough proximity to fold into the 
full functional label, which is dependent on at least two complementary 
labelled proteins associating with one another, indicating the formation of 
dimers, oligomers or larger aggregates.  The conditioned medium is 
collected from donor cells co-expressing the protein with each label and is 
applied to the acceptor culture.  
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Figure 3. Different conditioned medium experimental procedures. 1) A porous membrane barrier 
prevents direct contact between the donor and acceptor cultures, allowing only secreted factors of a 
particular size in the medium to pass between the two compartments 2) Medium from the donor 
culture is collected and a naïve acceptor culture is incubated in the conditioned medium 3) Before 
applying the medium from the donor culture to the acceptor culture, components of the conditioned 
medium are extracted or concentrated 4) The donor culture co-express protein labelled with one of 
two complimentary fragments that luminesce  when in close proximity with one another, which is 
dependent on self-association of at least two proteins labelled with one of each fragment. 
Application of conditioned medium obtained from the donor culture onto the acceptor culture will 
result in bioluminescence in acceptor cells only if the luminescent aggregate species are taken up by 
the acceptor culture. 
3 Evidence of cell-to-cell transfer of misfolding proteins through 
conditioned medium experiments 
Cell models have used a variety of different mammalian prion strains, in 
combination with immortalised and primary neuronal and non-neuronal cell 
lines, to explore the mechanisms of prion release and uptake between cells [59]. 
A strain is defined by a specific conformation that is adopted by the normal 
cellular PrPC prion during the conversion process to the aberrant scrapie PrPSc 
prion, which is then faithfully and stably propagated in a host [60]. This, in part, 
determines the pathological and biophysical properties of a particular strain. 
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Several studies have demonstrated that mammalian prion strains can propagate 
between neighbouring cells using conditioned medium, some in association with 
exosomes, but this may depend on the properties of the strain used as well as the 
cell type. For example, the use of neuron-like Neuro-2A cells overexpressing the 
mouse adapted scrapie prion strain 22L shows cell-to-cell transfer via 
conditioned medium, but the same cell line overexpressing another mouse 
adapted scrapie prion strain (RML) shows no or little transfer through the same 
route [76-78] (for a full review of cell models of mammalian prion strain 
propagation, see [79]). Building on experiments carried out on mammalian prion 
strains in conditioned medium, researchers have been able to demonstrate cell-
to-cell transfer of many other aggregation-prone proteins involved in 
neurodegenerative diseases using similar experimental procedures, a variety of 
aggregate species and different immortalised neuron-like cell lines (Table 1). 
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Experimental 
set up 
Protein of 
interest 
Disease Transferring 
species 
Cell line 
Membrane 
barrier 
Dipeptide 
repeat 
proteins 
from 
C9orf72 
hexanucleo
tide repeat 
expansions 
ALS N.C. NSC-34 [51] 
SOD1  ALS N.C. Neuro 2 A [45] 
Application onto 
acceptor culture 
Tau  
 
Alzheimer’s N.C. [80], 
Fibrils [81] 
HEK293 [80], 
 Primary 
neurons [81] 
 
Huntingtin 
(Q19 and 
Q103) 
Huntington’s N.C. HEK donors and 
SH-SY5Y 
acceptors [82] 
α-synuclein Parkinson’s Monomers, 
oligomers and 
fibrils [83] 
High and low 
molecular 
weight 
oligomers 
[84] 
SH-SY5Y donors 
and COS-7 
acceptors [83] 
Differentiated 
and 
undifferentiated 
SH-SY5Y [84] 
 
SOD1 ALS N.C. [45] 
 
Neuro 2 A [45] 
TDP-43 ALS N.C. HEK293 [27,74] 
Exosome 
isolation 
Yeast prion 
Sup35 (NM 
domain) 
N.A. Multimers 
[85] 
N.C. [86] 
Neuro2A [85,86] 
SOD1 ALS N.C.  NSC-34 [66] 
Complementary 
protein assay 
model 
Tau Alzheimer’s N.C. HEK293T [87] 
TDP-43 ALS Dimers, 
oligomers 
HEK293 [75] 
Table 1.  Examples of misfolding proteins involved in neurodegenerative diseases that undergo cell-
to-cell transfer in different conditioned medium experimental set ups. N.A., not applicable, N.C., not 
characterised. 
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4 Conditioned medium experiments using SOD1 or TDP-43 
4.1 Conditioned medium experiments using SOD1 
Earlier experiments using pre-formed fluorescently labelled variant SOD1H46R 
aggregates revealed that these aggregates could be endocytosed by Neuro 2A 
cells when exogenously applied to the culture medium [45]. These aggregates 
were capable of converting intracellular SOD1H46R in transfected Neuro 2A cells 
into puncta that persisted in culture even after the exogenous aggregates had 
been degraded. Cell-to-cell transfer of different fluorescently labelled aggregates 
was shown to occur between populations inoculated separately before mixing, 
even when separated by a 0.4 μm filter membrane, showing that cell-to-cell 
contact was not necessary for the transfer of these aggregates [45]. Further 
experiments involving a full-length variant SOD1 (SOD1G85R), a C-terminally 
truncated SOD1 variant (SOD1G127X, containing the dominantly inherited 
G127insTGGG mutation) and WT SOD1 have demonstrated that conditioned 
medium can propagate aggregates between cells [66,88]. In addition, misfolded 
SOD1G127X can interact with intracellular WT SOD1 in NSC-34 cells, converting it 
to a misfolded conformation by the formation of non-native SOD1 interchain 
disulphide bonds [88]. Moreover, overexpression of WT SOD1 in cell culture 
induces misfolding of a proportion of this intracellular SOD1, suggesting that a 
spontaneous misfolding event may trigger sALS through induced conversion of 
natively folded SOD1 by a pathological conformer [88]. The discovery that WT 
SOD1 is also involved in misfolding and aggregation is particularly significant, as 
this implicates it as a common pathological mechanism irrespective of whether 
ALS is sporadic or familial [44].  
 
Several GFP labelled SOD1 variants (SODA4V, SODG93A and SODG127X), as well as 
human WT SOD1-GFP, transiently overexpressed in NSC-34 cells caused 
increases in cell death 72 h post-transfection [66]. Western blot analysis and 
filter trap assays identified oligomeric aggregates (larger than the 0.2 μm 
membrane pore size) present in the culture medium, including those of WT 
SOD1, suggesting that dying cells can release aggregates directly into the 
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extracellular environment. However, this cell line is also known to release 
exosomes, and in stably transfected cells overexpressing different SOD1 variants, 
exosomes exposed misfolded SOD1 onto the surface of the membrane, in 
contrast to natively folded WT SOD1, which is normally localised in the lumen 
[44,66,89].  
 
Conditioned medium was collected from human embryonic kidney cells, 
HEK293, transiently transfected with SOD1 (SODG85R, SODG127X or WT SOD1) 48 h 
post-transfection, as these cells displayed resistance to misfolded SOD1 toxicity 
[66]. Naïve recipient cells expressing endogenous WT SOD1 were cultured in 
conditioned medium containing variant or WT SOD1 to determine whether or 
not seeding could be observed. Seeding was in fact serially propagated between 
cultures over five passages, providing very strong evidence for the prion-like 
propagation of misfolded SOD1 as a competent seed [66]. Together, this shows 
that both pathways dependent and independent on exosomes are involved in 
cell-to-cell transfer using conditioned medium. Exosome independent SOD1 
aggregates are taken up via macropinocytosis, a form of non-selective 
endocytosis characterised by ruffling in the plasma membrane, resulting in the 
engulfment of large fluid-phase molecules into vesicles [90]. The exosome 
independent uptake of SOD1 involves a mechanism specific to SOD1 but is not 
aggregate specific, as soluble SOD1 species are internalised with the same 
efficiency, suggesting that this process is receptor mediated [89]. Experiments 
with a microglial cell line have already shown that scavenger receptors 
participate in selective uptake of SOD1 [91].   
 
4.2 TDP-43 in conditioned medium experiments 
The SOD1 serial propagation model was also used to investigate whether or not 
there is a cross-seeding effect between TDP-43 and SOD1 through conditioned 
medium [74]. The culture medium of HEK293 cells transiently transfected with 
TDP-43 was collected after 48 h and centrifuged to remove cell debris, as with 
previous experiments.  WT TDP-43 and a variant lacking the nuclear localisation 
signal (TDP-43ΔNLS), causing it to remain in the cytoplasm and undergo 
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aggregation, were used. This medium was then supplemented with 25% fresh 
complete medium and applied to naïve cells for a 20 h incubation period. 
Quantitative immunoprecipitation confirmed that 20-40% of detectable 
endogenous WT SOD1 was misfolded in the lysate of cells incubated with either 
WT TDP-43 or TDP-43ΔNLS. A 15-25 fold drop in WT SOD1 occurred when 
endogenous SOD1 was knocked down in these cells, excluding the possibility 
that misfolded WT SOD1 was transferred from the original donor culture 
through the conditioned medium.  
 
Using the same model, the question as to whether or not TDP-43 pathology was 
being propagated to recipient cells alongside the misfolded SOD1 was 
investigated. The over-expressed TDP-43ΔNLS exhibited many of the pathological 
makers associated with TDP-43 in ALS, including the clear generation of C-
terminal truncated fragments (CTFs) and hyperphosphorylated TDP-43 found 
exclusively in cytoplasmic puncta. These markers, however, were not found in 
endogenously expressed TDP-43 in the naïve recipient cells incubated in the 
conditioned medium during the same 20 h time period, suggesting that the 
pathological TDP-43 could not confer its properties onto the endogenous 
intracellular TDP-43 in the same manner.  
 
Another recently published study described the application of exogenous 
seeding material, either the insoluble fraction of TDP-43 derived from HEK293 
cells transfected with WT FLAG-tagged TDP-43 (WT FL TDP-43) or ALS patient 
tissue, via chemical transfection methods to acceptor HEK293 cells over-
expressing WT FL TDP-43 [27]. The recipient cells showed increased levels of 
phosphorylated TDP-43 in response to exposure to both the cell and patient 
derived seeds, with the WT FL TDP-43 seeds showing a greater effect than the 
ALS patient inoculum, as demonstrated by immunocytochemistry and western 
blotting. This effect was further increased after serial passaging, using a 
subsequent set of recipient cells re-transfected with inoculum derived from the 
first set of re-transfected cells.  However, when conditioned medium collected 
from cells re-transfected with the seeds was incubated with naïve cells for 72 h, 
no cell-to-cell transfer was observed.  
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To date, there is only one reported cell model that demonstrates TDP-43 
transferring between cells via conditioned medium. This particular model uses a 
protein complementation technique based on a two-part luciferase reporter 
system to quantify intracellular dimers and oligomers, as determined by size 
exclusion chromatography [75]. TDP-43 was fused to the N-terminal or C-
terminal fragment of a luciferase (TDP-L1 and TDP-L2 respectively) and 
bioluminescence can only occur if these two constructs are both expressed and 
the proteins are interacting. Thus, the bioluminescence detected as a 
consequence of the interaction between the two luciferase fragments can be 
used to report on the aggregation status of the intracellular TDP-43.  HEK293 
cells were co-transfected with these constructs and the conditioned medium was 
collected after 60 h. Bioluminescence was detected in the conditioned medium, 
indicating that TDP-43 was present. When the conditioned medium was applied 
to naïve non-transfected HEK293 acceptor cells for 72 h, luciferase activity was 
detected in the acceptor cells even after repeated washing, showing that they 
were able to internalise the dimers or oligomers present in the medium. A major 
advantage of this strategy compared to other seeding experiments involving 
TDP-43 is that the TDP-43 is spontaneously internalised by recipient cells, rather 
than relying on lipofection to introduce the seed, which is less physiologically 
applicable to the disease process.  
5 Issues to be resolved in conditioned medium experiments using TDP-
43 
Considering the many similarities between SOD1 and TDP-43, which both show 
some evidence of prion-like propagation in vitro, it is surprising to find that one 
misfolded protein is so readily transmissible through conditioned medium, while 
the other appears unable to participate as efficiently. Differences in the 
properties of the two proteins, as well as in the experimental parameters of the 
various spreading models, may all contribute to explaining why cell-to-cell TDP-
43 transfer has not been conclusively observed so far, with the exception of the 
complementary protein assay model [75]. SOD1 and TDP-43 inclusions rarely co-
localise in sALS, and there is experimental evidence in cell models suggesting 
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that SOD1 and TDP-43 a are sequestered into distinct inclusions through 
different pathways [92], which could mean that these two proteins are involved 
in separate disease mechanisms. More recent evidence, showing that both WT 
TDP-43 and TDP-43ΔNLS can induce WT SOD1 aggregation in cell cultures via 
conditioned medium instead implies that there is a mechanistic overlap between 
the two proteins, and there may be other reasons why there is no clear evidence 
for cell-to-cell transfer of TDP-43 using conditioned medium [74]. 
 
A variety of explanations for the differences have been proposed, including 
variations in the incubation periods, that the concentration of secreted TDP-43 is 
too low for uptake or subsequent seeding inside acceptor cells, the aggregates 
are not stable, or that TDP-43 transfer may be exclusively dependent on cell-to-
cell contact [27]. The SOD1 model for conditioned medium transfer incubated 
the donor culture in medium for 48 h post-transfection before collecting, and 
incubated the acceptor culture for a further 20 h [66]. Using the same 
experimental set up, it was reported that TDP-43 did not undergo cell-to-cell 
transfer under the same time frame [74]. In the WT FL TDP-43 model it was 
unclear how long the donor culture was incubated before it was applied to the 
acceptor cells; therefore, although the incubation period for the acceptor culture 
was 72 h, the initial incubation period may not have been sufficient for TDP-43 
to accumulate in the medium [27]. The only TDP-43 model that reports 
spreading via conditioned medium incubated the donor culture for 60 h before 
applying this medium to naïve cells for a further 72 h, so it may be that TDP-43 
takes longer to be released and taken up at appreciable concentrations to allow 
the observation of internalisation of TDP-43 in acceptor cells [75]. 
 
Interestingly, in the studies that did not observe the transfer of TDP-43 via 
conditioned medium, the levels of TDP-43 present within the medium were not 
quantified, whereas these levels were confirmed in the study involving the 
protein complementation-based model monitored with bioluminescence [75]. 
Immunodetection techniques, including immunoprecipitation, could be used to 
determine whether TDP-43 is present at detectable levels. Even if TDP-43 is 
secreted by donor cells, it may be that the levels are too low in the reported 
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models to be detected in recipient cells. Concentrating the medium, or isolating 
exosomes as has been done using SOD1 conditioned medium, may provide better 
conditions for spreading through this route. TDP-43 uptake has been reported in 
several studies, but apart from the model using the protein complementation 
assay, most have relied on chemical transfection methods to facilitate 
internalisation, which is less physiologically relevant [22,26,27,75]. On the other 
hand, it is possible that the luciferase tags in the complementation assay cause 
perturbations to the conformation or stability of putative TDP-43 oligomers, so 
that the propagative species in this model may not be formed in the other 
systems.  
 
It is also possible that TDP-43 only undergoes cell-to-cell transfer through close 
contact between cells, but the fact that incubating WT SOD1 expressing recipient 
HEK293 cells with conditioned medium containing WT TDP-43, but not WT FUS, 
can induce SOD1 misfolding suggests that TDP-43 has an effect without 
intercellular contacts [74]. Furthermore, TDP-43 is found at elevated levels in 
CSF from ALS patients, providing a route by which TDP-43 pathology can 
disseminate over long distances within the CNS [70]. Different routes may have 
different efficiencies, with direct contact facilitating greater TDP-43 transfer than 
conditioned medium, but they may operate together rather than exclusively. 
Two recent models were used to observe spontaneous cell-to-cell transfer of 
TDP-43, one using turboGFP tagged TDP-43 variant G249A in NSC-34 culture, 
and the other employed SH-SY5Y cells stably expressing HA tagged WT TDP-43 
as the donor population [93,94]. In both cases, transfer took place under co-
culture conditions, and crucially neither use transfection to induce the transfer. 
These models may provide a good foundation for further exploring the 
contribution of conditioned medium versus cell contact using TDP-43.  
 
A significant hindrance to understanding fully the role of TDP-43 in ALS has been 
a lack of structural information for the full-length protein due to its high 
aggregation propensity. However, recent studies have provided detailed 
structural insights into the individual domains of TDP-43 at the atomic level 
using both X-ray crystallography and solution NMR techniques to demonstrate 
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the folded nature of the N-terminal and RRM domains and an intrinsically 
disordered C-terminal region[95-99]. This information has paved the way for 
insights into the structural dynamics of TDP-43 and also investigations of 
potential intra- and inter-molecular contacts that are likely to be pivotal for 
elucidating the structural nature of the aggregate species that are formed as part 
of the disease process. 
 
Furthermore, it is unclear which aggregated species are disease relevant, as 
there are conflicting reports regarding the importance of amyloid fibrils in the 
disease process. Two studies have found Thioflavin S positive TDP-43 inclusions 
in a small subset of post-mortem patient tissue, and another has shown that a 
synthetic peptide based on an aggregation-prone region of the C-terminus forms 
ThT positive fibrils in vitro that are capable of seeding aggregation and show 
neurotoxicity in cell cultures, suggesting that pathological TDP-43 has amyloid-
like properties [22,24,25,100]. In contrast, overexpression of full-length and the 
C-terminal fragment of TDP-43 in purified E. coli inclusion bodies results in the 
formation of amorphous aggregates, which lack any signatures of amyloid, but 
which are also highly toxic when present in the cytosol of cells [101]. Recently, 
there has been a shift in favour of the idea that smaller oligomeric species, rather 
than stable mature amyloid structures, are the main driver of neuropathology in 
neurodegenerative diseases [102,103]. This, however, poses additional 
challenges in determining which species are most relevant to the disease, as 
oligomers represent a very heterogeneous subset of aggregates in terms of size 
and structure [104]. 
 
Another factor to consider is the possibility that the properties of propagation 
and toxicity are not linked, meaning that species that are capable of cell-to-cell 
transfer may differ from the neurotoxic conformers, as is the case with 
mammalian prions [105,106]. For example, highly toxic species may reduce 
infectivity by causing neuronal cell death during the early stages of amyloid 
formation, terminating the process before the production of more infectious 
aggregates. Fibril rigidity may also affect these properties, as more stable 
amyloid aggregates are less likely to undergo fragmentation, generating fewer 
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‘seeds’ for further induced misfolding of monomers [55]. For two of the studies, 
the ‘seed’ was derived from clinically confirmed ALS patient tissue showing TDP-
43 positive inclusions, but the aggregates present have not been robustly 
characterised using biophysical techniques, and there is scope for heterogeneity 
between and within patient samples [27,107].  
 
The complexities of understanding the underlying mechanisms of the spread of 
disease in ALS and other neurodegenerative diseases, is of paramount 
importance to allow the development of effective therapeutic interventions. A 
number of robust techniques have been developed in recent years to tackle these 
questions, and it is clear that in systems for which we are able to gain insight into 
the structural attributes of the putative seeding aggregates, it is possible to begin 
to elucidate the mechanisms of cell-to-cell transfer. It is therefore clear that it is 
imperative to identify the disease-relevant aggregate species in the case of TDP-
43 associated ALS, in order to understand fully how propagation within the CNS 
takes place under disease conditions. Given the recent focus of many groups on 
defining the structural attributes of TDP-43 in both its physiological and 
pathological states, we believe it is possible to gain a fuller understanding of the 
relevance of amyloid and other aggregate species to the disease progression in 
ALS. 
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